Quarterly report pursuant to Section 13 or 15(d)

Segments

v2.4.0.8
Segments
 6 Months Ended
Jun. 30, 2014
Segment Reporting [Abstract]  
SEGMENTS
SEGMENTS
We currently manage our operations in two reportable segments, pharmaceuticals and diagnostics. The pharmaceuticals segment consists of two operating segments, our (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products, and vaccines, and (ii) the pharmaceutical operations we acquired in Chile, Mexico, Israel, Spain, Brazil, and Uruguay. The diagnostics segment consists of two operating segments, our (i) pathology operations we acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. There are no inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the three months ended June 30,
 
For the six months ended June 30,
(In thousands)
2014
 
2013
 
2014
 
2013
Product revenues:
 
 
 
 
 
 
 
Pharmaceuticals
$
21,392

 
$
18,618

 
$
41,219

 
$
34,145

Diagnostics
—

 
—

 
—

 
—

Corporate
—

 
—

 
—

 
—

 
$
21,392

 
$
18,618

 
$
41,219

 
$
34,145

Revenue from services:
 
 
 
 
 
 
 
Pharmaceuticals
$
—

 
$
—

 
$
—

 
$
—

Diagnostics
2,093

 
3,108

 
4,003

 
6,160

Corporate
60

 
80

 
120

 
120

 
$
2,153

 
$
3,188

 
$
4,123

 
$
6,280

Revenue from transfer of intellectual property:
 
 
 
 
 
 
 
Pharmaceuticals
$
—

 
$
1,300

 
$
285

 
$
13,800

Diagnostics
—

 
715

 
191

 
972

Corporate
—

 
—

 
—

 
—

 
$
—

 
$
2,015

 
$
476

 
$
14,772

Operating (loss) income:
 
 
 
 
 
 
 
Pharmaceuticals
$
(20,368
)
 
$
(4,528
)
 
$
(36,941
)
 
$
3,955

Diagnostics
(6,805
)
 
(6,750
)
 
(13,882
)
 
(16,384
)
Corporate
(7,038
)
 
(5,762
)
 
(13,174
)
 
(10,787
)
Less: Operating loss attributable to noncontrolling interests
(674
)
 
(943
)
 
(1,163
)
 
(1,540
)
 
$
(34,885
)
 
$
(17,983
)
 
$
(65,160
)
 
$
(24,756
)
Depreciation and amortization:
 
 
 
 
 
 
 
Pharmaceuticals
$
2,287

 
$
1,702

 
$
4,135

 
$
3,397

Diagnostics
1,716

 
1,704

 
3,408

 
3,393

Corporate
24

 
45

 
48

 
90

 
$
4,027

 
$
3,451

 
$
7,591

 
$
6,880

Revenues:
 
 
 
 
 
 
 
United States
$
2,153

 
$
5,203

 
$
4,599

 
$
21,052

Chile
7,852

 
8,482

 
15,136

 
16,223

Spain
5,666

 
5,153

 
11,815

 
9,477

Israel
6,307

 
3,995

 
10,853

 
6,567

Mexico
1,546

 
988

 
3,377

 
1,878

Uruguay
21

 
—

 
38


—

 
$
23,545

 
$
23,821

 
$
45,818

 
$
55,197


(In thousands)
June 30,
2014
 
December 31,
2013
Assets:
 
 
 
Pharmaceuticals
$
1,059,635

 
$
1,065,033

Diagnostics
110,454

 
116,944

Corporate
156,993

 
209,539

 
$
1,327,082

 
$
1,391,516

Goodwill:

 

Pharmaceuticals
$
175,036

 
$
175,408

Diagnostics
50,965

 
50,965

Corporate
—

 
—

 
$
226,001

 
$
226,373



During the three and six months ended June 30, 2014, one customer represented 21% and 15% of our total revenue, respectively. During the three and six months ended June 30, 2013, no customer represented more than 10% of our total revenue.
As of June 30, 2014, no customer represented more than 10% of our accounts receivable balance. As of December 31, 2013, no customer represented more than 10% of our accounts receivable balance.